Source Feed: The Globe and Mail
Author: Jennifer Yang
Publication Date: October 28, 2025 - 07:00
Excitement around Alzheimer’s treatment tempered by questions about efficacy, accessibility
October 28, 2025
Lecanemab is the first new treatment for Alzheimer’s disease to reach Canada in 20 years, and Health Canada’s recent authorization of the disease-modifying drug has understandably triggered hope and excitement.
But for some researchers and clinicians who treat the disease, the development also represents a complicated story – one where enthusiasm for a new and desperately needed drug is tempered by sobering realities around its efficacy, accessibility and impact on an already strained health care system.
Unpublished Newswire
New Department of Homeland Security regulations in the United States will, beginning Dec. 26, require all non-citizens (including Canadians)
to be photographed
while entering or leaving the country.
The initiative is intended to build a comprehensive biometric data collection aimed at...
October 28, 2025 - 11:54 | Chris Knight | National Post
The Ottawa Police Service is appealing to the public to help identify a "person of interest" in relation to a fatal stabbing near Ottawa Trainyards earlier this month. Read More
October 28, 2025 - 11:37 | Paula Tran | Ottawa Citizen
Live Nation Canada says a planned overhaul of a popular waterfront music spot will increase summer lawn seating and add movable enclosures for winter concerts.
October 28, 2025 - 11:31 | Globalnews Digital | Global News - Canada
Comments
Be the first to comment